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a b s t r a c t 
Context: Metastatic adrenocortical carcinoma (ACC) is an aggressive malignancy with a poor prognosis 
and limited therapeutic options. A subset of ACC is due to Lynch syndrome, an inherited tumor syndrome 
resulting from germline mutations in mismatch repair (MMR) genes. It has been demonstrated that sev- 
eral cancers characterized by MMR deficiency are sensitive to immune checkpoint inhibitors that target 
PD-1. Here, we provide the first report of PD-1 blockade with pembrolizumab in a patient with Lynch 
syndrome and progressive cortisol-secreting metastatic ACC. 
Case report: A 58-year-old female with known Lynch syndrome presented with severe Cushing’s syn- 
drome and was diagnosed with a cortisol-secreting ACC. Three months following surgical resection and 
adjuvant mitotane therapy the patient developed metastatic disease and persistent hypercortisolemia. She 
commenced pembrolizumab, but her second cycle was delayed due to a transient transaminitis. Com- 
puted tomography performed after 12 weeks and 2 cycles of pembrolizumab administration revealed 
significant disease progression and treatment was discontinued. After 7 weeks, the patient became jaun- 
diced and soon died due to fulminant liver failure. 
Conclusion: Treatment of MMR-deficient cortisol-secreting ACC with pembrolizumab may be ineffec- 
tive due to supraphysiological levels of circulating corticosteroids, which may in turn mask severe drug- 
induced organ damage. 
© 2018 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Adrenocortical carcinoma (ACC) is a rare and aggressive can-
er with limited therapeutic options for patients with advanced
isease. In adults, the majority of ACC are sporadic; however,
t is recognized that a subset of ACC is associated with Lynch
yndrome, an autosomal dominant tumor syndrome caused by
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ossess a high somatic mutation burden and present a diverse
epertoire of neoantigens which in turn enhances tumor immuno-
enicity and thus tumor-specific T cell responses. This is relevant
n the context of the important advances in T cell immune check-
oint targeted cancer immunotherapy, in particular with drugs
hat target programmed death-ligand 1 (PD-L1). PD-L1 is expressed
n the surface of tumor cells and inhibits T cell activation through
inding of its cognate coinhibitory T cell receptor, PD-1. In many
umors, PD-L1 expression is upregulated, enabling tumor cells to
vade the host immune system through inhibition of activated
 cells. Immune checkpoint inhibitors that target this pathway,
y blocking either PD-1 or PD-L1, have led to significant clinical
esponses in some patients with different cancer types [3] . Indeed,nder the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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secent landmark studies have now demonstrated that MMR- 
eficient tumors are more responsive to PD-1 blockade with the 
nti-PD-1 antibody pembrolizumab than MMR-proficient tumors, 
ith response rates exceeding 50% [4] . Based on these data, pem-
rolizumab was granted Food and Drug Administration approval 
or the treatment of unresectable or metastatic, microsatellite 
nstability-high (MSI-H) or MMR-deficient solid tumors regard- 
ess of tumor site or histology. One of the limitations of T cell
heckpoint targeted cancer immunotherapy are T cell mediated 
utoimmune side effects, that can be severe and life threatening,
ut can be ameliorated with immune suppressive medications, 
uch as glucocorticoids [5] . This demonstrates that the enhanced T
ell response may be sensitive to or prevented by the high levels
f cortisol that are found in patients with cortisol secreting ACC. 
Here, we describe the first reported case of a cortisol-secreting 
etastatic ACC treated with pembrolizumab in a patient with 
ynch syndrome. 
ethods and materials 
MMR immunohistochemistry was performed using the Ven- 
ana Benchmark MMR panel: MLH-1 (M1), PMS2 (EPR3947), MSH2 
G219-1129), and CONFIRM anti-MSH6. PD-L1 immunohistochem- 
stry was performed using the PD-L1 IHC 22C3 pharmDx test 
Dako) and β2-microglobulin immunohistochemistry was per- 
ormed using a polyclonal rabbit antihuman antibody (Dako, Cat# 
0072). Immunohistochemistry was performed on 4 μm sections 
f paraffin embedded tumor tissue, in accordance with the manu- 
acturer’s guidelines and interpreted by an experienced pathologist 
OG). 
esults and clinical case description 
A 58-year-old female presented with a 2 year history of pro-
ressive weight gain and reduced mobility. Her medical history 
as significant for Lynch syndrome due to a pathogenic mutation 
n MSH2 (p.Asn263fs). The patient had previously undergone an 
bdominal hysterectomy and bilateral salpingo-oophorectomy fol- 
owing identification of cervical cell dysplasia. Annual colonoscopic 
xaminations were normal. There was no history of glucocorticoid 
xposure. Clinically, the patient was hypertensive (165/130 mmHg) 
ith an elevated body mass index (30 kg/m 2 ). She was hirsute,
rofoundly plethoric with widespread ecchymoses and exhibited a 
arked proximal myopathy. Abdominal examination revealed vi- 
laceous abdominal striae, in the absence of any organomegaly 
r palpable masses. Biochemical investigations revealed marked 
utonomous adrenocorticotrophic hormone-independent hypercor- 
isolemia (urinary free cortisol 1870 nmol/24 h [normal range: 
 146 nmol/24 h]; adrenocorticotrophic hormone < 5 ng/L (nor- 
al range: < 50 ng/L)) ( Fig. 1 A ) and hyperandrogenism (testos-
erone 4.8 nmol/L [normal range: 0.2–3 nmol/L]); androstenedione 
2.7 nmol/L [normal range: 1.4–4.3 nmol/L]). Computed tomogra- 
hy (CT) demonstrated an 11 cm × 7 cm heterogeneous lesion aris-
ng from the left adrenal and no evidence of metastatic disease
 Fig. 1 B) . 
The patient underwent an uncomplicated left adrenalectomy 
nd nephrectomy. Subsequent pathological examination of the re- 
ected tumor confirmed a stage III ACC (modified Weiss Score 
). Few tumor infiltrating lymphocytes were identified and tumor 
D-L1 expression was low ( < 1%) ( Fig. 2 A and B) . Immunohisto-
hemical analysis of the tumor demonstrated an isolated loss of 
SH2 and MSH6 expression with preserved expression of MLH1 
nd PMS2 ( Fig. 2 C–F). Adjuvant mitotane therapy (up to a maxi-
um tolerated dose of 2,0 0 0 mg each day) was commenced with
oncomitant hydrocortisone replacement therapy (40 mg daily in 
ivided doses). Three months following surgery the patient developed wors- 
ning abdominal pain. CT revealed tumor recurrence in the left 
drenal bed and new hepatic metastases ( Fig. 1 B). In view of
isease recurrence in the context of a MMR-deficient tumor, the 
atient was commenced on pembrolizumab (2 mg/kg) in com- 
ination with mitotane (2,0 0 0 mg daily). Following the first cy-
le of pembrolizumab, the patient developed a mild elevation 
f serum alanine aminotransferase (peak ALT 208 U/L [normal 
ange: 7–40 U/L]). Since the differential diagnosis for the eleva- 
ion of serum ALT included mitotane-induced hepatotoxicity and 
mmunotherapy-induced autoimmune hepatitis, mitotane was dis- 
ontinued and the second cycle of pembrolizumab was delayed. 
ithin 14 days of discontinuing mitotane, liver function had im- 
roved (ALT 129 U/L) and continued to do so when assessed 9 days
ater (ALT 70 U/L). During this period metyrapone was commenced 
t a dose of 2,0 0 0 mg per day; however, a 24 hour urinary cor-
isol rose to 1,0 6 6 nmol/24 h ( Fig. 1 A) . Metyrapone was further
ncreased to 3,0 0 0 mg daily and the patient proceeded to receive
 second cycle of pembrolizumab without any further disturbance 
n liver function tests, although treatment tolerance was poor, due 
o nausea, vomiting, and fatigue. Twelve weeks following initiation 
f treatment, CT imaging revealed significant disease progression, 
ith both rapidly increased size of the relapsed disease at the pri-
ary site and multiple new liver metastases ( Fig. 1 B ). 
The clinical management was changed to focus on best 
upportive care and pembrolizumab treatment was, therefore, 
iscontinued. Seven weeks later, the patient was admitted to 
ospital, grossly jaundiced (bilirubin 371 μmol/L [normal range: 
–20 μmol/L]). Biochemical indices of liver function were markedly 
eranged with ALT 1,553 U/L (normal range: 7–40 U/L); alkaline 
hosphatase 530 U/L (normal range: 30–130 U/L); and interna- 
ional normalized ratio (3.7; Fig. 1 A ). Liver ultrasound showed only
imited increase in size of liver metastases with no new lesions
dentified. Viral hepatitis serology was negative. A liver biopsy was 
ot feasible due to the presence of coagulopathy and rapid clinical
eterioration. The possibility of pembrolizumab-induced autoim- 
une hepatitis could not be excluded, so methylprednisolone (2 
g/kg) and mycophenolate mofetil (500 mg twice daily) were 
ommenced. However, the patient developed fulminant liver fail- 
re and died 3 days later. Both the family and coroner declined
ost mortem examination. 
iscussion 
In 2017, the Food and Drug Administration granted accelerated 
pproval for pembrolizumab use in any solid tumor shown to be
SI-high or MMR-deficient. This decision was based on clinical 
rial data demonstrating high response rates in patients with ad- 
anced cancer whose tumors had these genetic signatures [4,6] . 
ost of the patients had received multiple preceding lines of treat-
ent. In their most recent study, Le et al investigated the efficacy
f pembrolizumab in patients with progressive MMR-deficient tu- 
ors across 12 different cancer types, and reported an objective 
esponse rate of 53% [4] . 
ACC was not represented in these initial studies, but is a
ecognized Lynch syndrome associated malignancy [1,2] . Whether 
poradic or associated with an inherited tumor syndrome, the 
tandard treatment for patients with good performance status 
nd unresectable or metastatic ACC is currently combination 
hemotherapy consisting of etoposide, doxorubicin, cisplatin, and 
itotane. Unfortunately, this combination therapy is associated 
ith dose - limiting side effects and serious adverse events, 
hile only resulting in a modest improvement in median overall 
urvival [7] . Therefore, there remains an unmet therapeutic need 
or patients with advanced ACC. That MMR-deficient cancers are 
ensitive to immune checkpoint blockade provides a potential 
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Fig. 1. Time course of laboratory and radiological results. (A) The 24-hour urinary cortisol and ALT concentrations plotted against time (days). Solid line indicates urinary 
free cortisol levels. Dashed line indicates ALT levels. (B) Representative cross-sectional CT images at diagnosis (day 0), postadrenalectomy (day 91), and following initiation 
of pembrolizumab therapy (day 180). White arrowheads indicate the primary tumor at diagnosis and, following treatment, sites of local and metastatic recurrence. 
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rrecision medicine opportunity for the relevant subset of patients
ith ACC. 
Immune checkpoint inhibitors are significantly improving clin- 
cal outcomes in some advanced cancers, although most patients
rogress with their disease despite treatment. Both primary and
cquired resistance mechanisms have been described, and may
e secondary to the intrinsic and extrinsic factors to tumor cells
3,8,9] . One of the cancer cell intrinsic immune escape mechanisms
s impaired antigen presentation by cancer cells due to reduced
xpression of peptide-MHC processing components [3] . In our pa-
ient’s primary tumor, we found preserved β2-microglobulin ex-
ression, with a distinct membranous staining pattern within the
arenchyma ( Fig. 2 G ). While this is not a comprehensive assess-
ent of the antigen processing pathway, these data suggest that
ther mechanisms may account for the immunotherapy failure we
bserved. As such, the impact of systemic glucocorticoid exposure
n immunotherapy responsiveness should be considered, but is in-
ompletely understood [10] . The case we describe provides a rare
pportunity to examine the relationship of systemic immune sup-
ression with increased MMR-deficiency mediated cancer cell anti-
enicity in the context of cancer immunotherapy. 
Glucocorticoids regulate many aspects of immune function, in-
luding suppression of the cellular Th1 immune responses that are
stensibly required for the antitumor effects of immune checkpoint
nhibitors. Indeed, preclinical studies in a rodent model of pan-reatic ductal adenocarcinoma demonstrated that elevated plasma 
orticosterone levels impaired immunotherapy outcome [11] . The
esected ACC tumor in the case described here was character-
zed by a paucity of tumor infiltrating T lymphocytes. Typically,
MR-deficient tumors display an increased number of lympho-
ytes within the tumor which correlates with response to immune
heckpoint inhibition and prognosis [3] . The discordance between
hese findings and our case may reflect the suppressive effects of
lucocorticoids on T cell chemotaxis and migration, possibly poten-
iated by the high local concentration in the tumor microenviron-
ent, and, at least in part, explains the poor response to immune
heckpoint blockade. Glucocorticoids have also been shown to in-
uce Fas-L overexpression in preclinical models of ACC, suggesting
xistence of additional glucocorticoid-regulated mechanisms that 
ay impair response to immunotherapy [12] . Furthermore, our
ase demonstrates the potential for fluctuating levels of endoge-
ous glucocorticoids to potentially influence response to immune-
elated adverse events. 
The patient described in this report developed transient liver
ysfunction after the first cycle of pembrolizumab. Immunotherapy
ith pembrolizumab was discontinued after cycle 2 due to rapid
isease progression. The patient developed fatal liver failure that
id not respond to treatment with immune suppression 7 weeks
fter stopping pembrolizumab. Hepatitis is a recognized immune-
elated adverse event associated with pembrolizumab, occurring 
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Fig. 2. (A) Representative hematoxylin and eosin-stained photomicrograph of ACC. (B–G) Immunohistochemical analyses of protein expression in resected ACC. (B) PD-L1 
expression in tumor cells was < 1%. The tumor did not express (C) MSH2 or (E) MSH6 but expression of (D) MLH1, (F) PMS2, and (G) β2-microglobulin was preserved (scale 
bar = 200 μm). 
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tn approximately 1% of all treated patients. Higher rates of liver
amage have been reported when potentially hepatotoxic agents, 
uch as dacarbazine, are given in combination with checkpoint 
nhibitors [13] . We speculate that concurrent treatment with the 
epatotoxic agents, mitotane and metyrapone, may have increased 
he risk of liver injury, but cannot completely exclude the possibil-
ty that liver failure was due to disease progression. It is notable
hat conflicting data exist whether the occurrence of immune- 
elated adverse events are associated with improved response to 
reatment [14] . This again could be reflective of the pretreatment
tate of T cell infiltration into tumor and normal tissue. In the case
iscussed here, it is conceivable that the very high intratumoral 
ortisol concentration may have caused a more profound intra- 
umoral immune suppression when compared to the liver tissue. 
his could have reduced the therapeutic index and caused pem- 
rolizumab toxicity in the absence of antitumor efficacy. 
Glucocorticoids are the mainstay of treatment for immune- 
elated adverse events, and to date, there is no evidence thatheir use once the effect of immunotherapy has been es- 
ablished impacts upon treatment outcomes. However, in this 
ase glucocorticoids were elevated when treatment commenced, 
hich represents a distinct clinical scenario. Our report high- 
ights a need for further investigations to determine whether 
upraphysiological concentrations of glucocorticoid (endogenous 
r exogenous) induce a degree of systemic immunosuppres- 
ion that impacts upon clinical response to immune checkpoint 
nhibition. 
In summary, we report the first description of pembrolizumab 
reatment in a MMR-deficient and cortisol-secreting metastatic 
CC. The therapy was not effective and rapid disease progression 
ccurred. Although no single case should be used to argue against
ecommendations based on comprehensive scientific and clinical 
nvestigation, it is important to acknowledge potential immuno- 
uppressive phenomena that may reduce the efficacy of cancer 
mmunotherapy, and cases can serve as a salutary reminder that 
here can be exceptions to the rule. 
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